PT-141
Bremelanotide
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.
PT-141 Dosing Guide
Primary Benefits
- FDA-approved for hypoactive sexual desire disorder (HSDD)
- Increases sexual desire and motivation through brain pathways
- Enhances sexual arousal and satisfaction
- Reduces distress related to low sexual desire
- Works through central nervous system, not vascular system
How It Works
PT-141 functions as a selective melanocortin-4 receptor (MC4R) agonist in the central nervous system. Upon subcutaneous administration, bremelanotide crosses the blood-brain barrier and binds to MC4R receptors in the hypothalamus and other limbic structures involved in sexual behavior. This activation triggers downstream signaling cascades involving cyclic adenosine monophosphate (cAMP) and protein kinase A pathways, ultimately enhancing sexual motivation and desire through neuronal mechanisms rather than peripheral vascular effects.
Quick Reference
Typical Dosage Range
The FDA-approved dosing regimen for PT-141 is 1.75 mg administered subcutaneously via auto-injector at least 45 minutes before anticipated sexual activity. The maximum frequency is 8 injections per 30-day period, with no more than one dose per 24-hour period. No dose escalation or titration is required - the therapeutic dose is fixed at 1.75 mg. Pre-medication with anti-emetics may be considered for patients experiencing significant nausea, though tolerance typically develops after 2-3 uses.
Administration Methods
PT-141 is administered via subcutaneous injection using the Vyleesi auto-injector device. Injection sites include the abdomen (avoiding 2 inches around navel) or anterior thigh. Site rotation is recommended to minimize injection site reactions. The auto-injector is single-use and pre-filled with 1.75 mg of bremelanotide. Patients should be trained on proper injection technique including site preparation with alcohol, perpendicular needle insertion, and proper disposal. The medication should be stored refrigerated but can be at room temperature for up to 24 hours before use.
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.